Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine

INTRODUCTION: As a primary stability-indicating parameter, potency should be strategically evaluated during each phase of vaccine development. Herein, we present potency testing during the early clinical development of the Schistosoma mansoni (Sm) Tetraspanin-2 vaccine formulated on Alhydrogel (Sm-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangzhao, Hoeweler, Lara, Keegan, Brian, Peng, Jin, Scholte, Larissa, Hotez, Peter, Bottazzi, Maria Elena, Diemert, David, Bethony, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209742/
https://www.ncbi.nlm.nih.gov/pubmed/34169270
http://dx.doi.org/10.1016/j.jvacx.2021.100100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209742/
https://www.ncbi.nlm.nih.gov/pubmed/34169270
http://dx.doi.org/10.1016/j.jvacx.2021.100100

Ejemplares similares